LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Listă Acțiuni・Omeros Corp

Omeros Corp

Deschisă

Sector Sănătate

3.9 -0.76

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.79

Maxim

4.01

Indicatori cheie
By Trading Economics
Venit	-18M -56M
EPS	-0.15
EBITDA	-48M

Dividende
By Dow Jones
Următoarele câștiguri	7 nov. 2024

Statistici piață
By TradingEconomics
Capitalizare de piață	-9.5M 216M
Deschiderea anterioară	4.66
Închiderea anterioară	3.9

Sentimentul știrilor

By Acuity

23%

77%

32 / 365 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

3.86 / 3.95 Suport & Rezistență

Omeros Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 sept. 2024, 01:45 UTC

Câștiguri

Preview -- Barron's

13 sept. 2024, 20:03 UTC

Top știri

Walgreens to Pay $106.8 Million Over Alleged Fraudulent Healthcare Billings

15 sept. 2024, 23:47 UTC

Market Talk

Gold Edges Higher Amid Mild Dollar Weakness -- Market Talk

15 sept. 2024, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2024, 23:03 UTC

Market Talk

Australian Bond Traders Watchful as Fed Easing Nears -- Market Talk

15 sept. 2024, 16:52 UTC

Top știri

Boeing Machinist Strike Adds Cash Crunch to New CEO's Rescue Mission -- WSJ

15 sept. 2024, 09:30 UTC

Top știri

Interest Rates Are Too High. The Fed Should Cut by a Half Point. -- WSJ

15 sept. 2024, 07:00 UTC

Top știri

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

14 sept. 2024, 14:09 UTC

Top știri

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- Update 1 -- WSJ

14 sept. 2024, 13:25 UTC

Top știri

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- WSJ

14 sept. 2024, 09:30 UTC

Top știri

Why a Fed Rate Cut Won't Solve the Housing Wealth Gap -- WSJ

14 sept. 2024, 09:30 UTC

Top știri

Americans Are Falling Behind on Their Bills. Wall Street Is Alarmed. -- WSJ

14 sept. 2024, 03:00 UTC

Top știri

What Scared Ford's CEO in China -- WSJ

14 sept. 2024, 03:00 UTC

Top știri

What Scared Ford's CEO in China -- WSJ -2-

14 sept. 2024, 00:01 UTC

Top știri

Why 96% of Boeing's Machinists Voted to Go on Strike -- Update

13 sept. 2024, 21:14 UTC

Top știri

Why 96% of Boeing's Machinists Voted to Go on Strike -- WSJ

13 sept. 2024, 21:06 UTC

Top știri

Starliner Astronauts Say NASA Ran Short of Time to Test Boeing Craft -- WSJ

13 sept. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

13 sept. 2024, 20:47 UTC

Market Talk

Saudi Arabia Credit Outlook Raised to Positive on Economic Investments -- Market Talk

13 sept. 2024, 20:44 UTC

Achiziții, Fuziuni, Preluări

Schlumberger Stock Was Once as Hot as Nvidia. Why It's a Buy. -- Barrons.com

13 sept. 2024, 20:41 UTC

Top știri

Berkshire Hathaway's Stock Is So Rich Even Berkshire Is Buying Less of It -- Update

13 sept. 2024, 20:31 UTC

Câștiguri

These Stocks Moved the Most Today: Adobe, Boeing, Trump Media, Oracle, Uber, RH, Moderna, Etsy, and More -- Barrons.com

13 sept. 2024, 20:13 UTC

Achiziții, Fuziuni, Preluări

BlackRock: Expects to Close Previously Announced Acquisition of Global Infrastructure Partners on Oct 1 >BLK

13 sept. 2024, 20:10 UTC

Achiziții, Fuziuni, Preluări

BlackRock Announces Expected Closing Date For Acquisition Of Global Infrastructure Partners >BLK

13 sept. 2024, 20:02 UTC

Achiziții, Fuziuni, Preluări

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13 sept. 2024, 20:02 UTC

Achiziții, Fuziuni, Preluări

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13 sept. 2024, 19:44 UTC

Market Talk

Treasury Yields Fall as Odds of 50bp Fed Cut Rise -- Market Talk

13 sept. 2024, 19:20 UTC

Market Talk

Crude-Oil Futures End Week With Small Gains -- Market Talk

13 sept. 2024, 19:09 UTC

Market Talk

U.S. Natural-Gas Futures Post Weekly Gain -- Market Talk

13 sept. 2024, 18:01 UTC

Market Talk

Gold Analysts Call For New Leg Of Rally -- Market Talk

Comparație

Modificare preț

Omeros Corp Așteptări

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor Omeros Corp - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

3.86 / 3.95Suport & Rezistență

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

32 / 365 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Omeros Corp

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its lead drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens replacement for adult and pediatric patients. Its drug candidate narsoplimab is the subject of a biologics license application (BLA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). It also has multiple Phase III and Phase II clinical-stage development programs in its pipeline, which are focused on complement-mediated disorders, including immunoglobulin A (IgA) nephropathy, atypical hemolytic uremic syndrome (aHUS) and COVID-19.